Next Article in Journal
Impact of Dental Midline Shift on the Perception of Facial Attractiveness in Young Adults
Previous Article in Journal
Facing Life in Old Age: Exploring Resilience in Older Adults with Bipolar Disorder
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 13
Issue 13
10.3390/jcm13133943
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to J. Clin. Med. 2023, 12(5), 1861.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Liu et al. Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. J. Clin. Med. 2023, 12, 1861

by
Yang Liu
1,†,
Chang-Lin Wang
2,†,
Zhong-Qi Pang
1,†,
Ke Gao
1,
Lin-Kun Shen
1,
Wan-Hai Xu
2,* and
Ming-Hua Ren
1,*
1
Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
2
Department of Urology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Clin. Med. 2024, 13(13), 3943; https://doi.org/10.3390/jcm13133943
Submission received: 11 January 2024 / Accepted: 22 February 2024 / Published: 5 July 2024
(This article belongs to the Section Nephrology & Urology)
Browse Figure
Versions Notes
In the original publication [1], there was a mistake in Figure 5 and Figure S1 as published. The authors found an inconsistency between the image labeled “MMP2” in Figure 5E of the article and the records in the original experimental notebook; to ensure the accuracy of the result, Figure 5E needs to be updated. Since the image of “MMP2” in Figure S1 corresponds to Figure 5E, the image of “MMP2” in Figure S1 needs to be updated simultaneously. The corrected Figure 5 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Liu, Y.; Wang, C.-L.; Pang, Z.-Q.; Gao, K.; Shen, L.-K.; Xu, W.-H.; Ren, M.-H. Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. J. Clin. Med. 2023, 12, 1861. [Google Scholar] [CrossRef] [PubMed]
Jcm 13 03943 g005
Figure 5. (A): PIK3CG, AKT, CTNNB1, MMP9 and MMP2 differentially expressed heatmap among the integrin α6β1-high group and integrin α6β1-low group. (B): Correlation analysis of ITGA6, ITGB1, PIK3CG, AKT, CTNNB1, MMP9 and MMP2. (C): PPI analysis of ITGA6, ITGB1, PIK3CG, AKT, CTNNB1, MMP9 and MMP2. (D): Western blot was used to detect the AKT, P-Akt, E-cadherin, β-catenin and Vimentin protein expression of different concentrations of the endostatin 33 peptide (200 µg/mL and 400 µg/mL) and 5% glucose solution groups in C4-2 cells. (E): Western blot was used to detect the MMP2 and MMP9 protein expression of the 33 polypeptide group, PEP06 group and 5% glucose solution group in C4-2 cells, respectively. (F): Western blot was used to detect the ITGA6, ITGB1, P-AKT, E-cadherin, β-catenin, Vimentin, MMP9 and MMP2 of the integrin α6β1 knockdown group, integrin α6β1 knockdown +PI3K activation group and control group in C4-2 cells. (* stands for p value < 0.05).
Figure 5. (A): PIK3CG, AKT, CTNNB1, MMP9 and MMP2 differentially expressed heatmap among the integrin α6β1-high group and integrin α6β1-low group. (B): Correlation analysis of ITGA6, ITGB1, PIK3CG, AKT, CTNNB1, MMP9 and MMP2. (C): PPI analysis of ITGA6, ITGB1, PIK3CG, AKT, CTNNB1, MMP9 and MMP2. (D): Western blot was used to detect the AKT, P-Akt, E-cadherin, β-catenin and Vimentin protein expression of different concentrations of the endostatin 33 peptide (200 µg/mL and 400 µg/mL) and 5% glucose solution groups in C4-2 cells. (E): Western blot was used to detect the MMP2 and MMP9 protein expression of the 33 polypeptide group, PEP06 group and 5% glucose solution group in C4-2 cells, respectively. (F): Western blot was used to detect the ITGA6, ITGB1, P-AKT, E-cadherin, β-catenin, Vimentin, MMP9 and MMP2 of the integrin α6β1 knockdown group, integrin α6β1 knockdown +PI3K activation group and control group in C4-2 cells. (* stands for p value < 0.05).
Jcm 13 03943 g005
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Liu, Y.; Wang, C.-L.; Pang, Z.-Q.; Gao, K.; Shen, L.-K.; Xu, W.-H.; Ren, M.-H. Correction: Liu et al. Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. J. Clin. Med. 2023, 12, 1861. J. Clin. Med. 2024, 13, 3943. https://doi.org/10.3390/jcm13133943

AMA Style

Liu Y, Wang C-L, Pang Z-Q, Gao K, Shen L-K, Xu W-H, Ren M-H. Correction: Liu et al. Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. J. Clin. Med. 2023, 12, 1861. Journal of Clinical Medicine. 2024; 13(13):3943. https://doi.org/10.3390/jcm13133943

Chicago/Turabian Style

Liu, Yang, Chang-Lin Wang, Zhong-Qi Pang, Ke Gao, Lin-Kun Shen, Wan-Hai Xu, and Ming-Hua Ren. 2024. "Correction: Liu et al. Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. J. Clin. Med. 2023, 12, 1861" Journal of Clinical Medicine 13, no. 13: 3943. https://doi.org/10.3390/jcm13133943

APA Style

Liu, Y., Wang, C.-L., Pang, Z.-Q., Gao, K., Shen, L.-K., Xu, W.-H., & Ren, M.-H. (2024). Correction: Liu et al. Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. J. Clin. Med. 2023, 12, 1861. Journal of Clinical Medicine, 13(13), 3943. https://doi.org/10.3390/jcm13133943

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop